Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study

ConclusionsAccording to our results, ICIs monotherapy and immune-based combinations were associated with higher risk of all-grade and grade 3 –4 hypertransaminasemia. Monitoring liver function should be recommended in cancer patients treated with ICIs monotherapy or immune-based combination, and in case of underlying liver disease, a careful risk–benefit assessment appears as a mandatory need.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research